Pathology’s Precision Oncology Mandate

0

1. Advances in bladder cancer treatment focus on precision medicine.

2. Genetic biomarkers via NGS are crucial for guidance.

3. PD-L1 and FGFR3 tests are highlighted in guidelines.

4. Collaboration among specialists is essential.

5. Challenges include testing disparities and delays.

6. Rapid testing may enhance accessibility.

7. Pathologists play a key role in interpreting genetic tests.

8. Future care requires speed, collaboration, and education.